[{"address1": "200 Greenhill Road", "city": "Eastwood", "state": "SA", "zip": "5063", "country": "Australia", "phone": "61 8 8150 7400", "website": "https://www.bionomics.com.au", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Spyridon  Papapetropoulos M.D., Ph.D.", "age": 50, "title": "CEO, President & Director", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 522982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Doolin", "age": 58, "title": "Senior Vice President of Clinical Development", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 210258, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy M. Cunningham CPA, M.B.A.", "age": 60, "title": "Chief Financial Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julie  Kerner Ph.D.", "title": "Senior Vice President of Business Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark A. Smith M.D., Ph.D.", "age": 68, "title": "Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.bionomics.com.au/page.php?section=34", "maxAge": 86400, "priceHint": 4, "previousClose": 0.6398, "open": 0.654, "dayLow": 0.42, "dayHigh": 0.655, "regularMarketPreviousClose": 0.6398, "regularMarketOpen": 0.654, "regularMarketDayLow": 0.42, "regularMarketDayHigh": 0.655, "beta": -0.123, "forwardPE": -0.2361828, "volume": 1352961, "regularMarketVolume": 1352961, "averageVolume": 949058, "averageVolume10days": 223630, "averageDailyVolume10Day": 223630, "bid": 0.4027, "ask": 0.4672, "bidSize": 100, "askSize": 100, "marketCap": 5819583, "fiftyTwoWeekLow": 0.42, "fiftyTwoWeekHigh": 5.3, "priceToSalesTrailing12Months": 8.791177, "fiftyDayAverage": 0.63878, "twoHundredDayAverage": 0.910765, "currency": "USD", "enterpriseValue": 832273600, "floatShares": 1350079860, "sharesOutstanding": 13247400, "sharesShort": 120378, "sharesShortPriorMonth": 333372, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0091, "heldPercentInsiders": 0.55912, "heldPercentInstitutions": 0.27048, "shortRatio": 0.9, "shortPercentOfFloat": 0.0111, "impliedSharesOutstanding": 8159640, "bookValue": 2.715, "priceToBook": 0.1618048, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -31007448, "trailingEps": -2.11, "forwardEps": -1.86, "enterpriseToRevenue": 1257.249, "enterpriseToEbitda": -32.353, "52WeekChange": -0.8942169, "SandP52WeekChange": 0.36246562, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "BNOX", "underlyingSymbol": "BNOX", "shortName": "Bionomics Limited - American De", "longName": "Bionomics Limited", "firstTradeDateEpochUtc": 1639665000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "4e477dfa-aa36-3df0-8418-7ef77e024c33", "messageBoardId": "finmb_3331473", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.4393, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.0, "targetMedianPrice": 6.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 14866263, "totalCashPerShare": 0.008, "ebitda": -25724844, "totalDebt": 1571516, "quickRatio": 3.501, "currentRatio": 3.811, "totalRevenue": 661980, "debtToEquity": 5.413, "revenuePerShare": 0.072, "returnOnAssets": -0.35127, "returnOnEquity": -0.80799, "freeCashflow": -13576108, "operatingCashflow": -26641194, "revenueGrowth": 0.093, "operatingMargins": -94.66236, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-10-01"}]